RGNX
REGENXBIO Inc. · NASDAQ
- Market cap
- $478.7M
REGENXBIO Inc. (RGNX) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 10 wire items for RGNX, including 4 insider trades, 2 earnings updates and 2 SEC filings. The most recent was published Nov 10, 2026.
RGNX rankings
Financial highlights
Full financials- Revenue, TTM
- $153.91M
- Revenue growth
- -4.6%
- Net income, TTM
- -$175.23M
- Net margin
- -113.9%
- Free cash flow, TTM
- -$154.80M
- Cash
- $95.80M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks60+150%
2026-05-242026-11-15
Mix2590d
- Insider8(32%)
- Other7(28%)
- SEC Filings6(24%)
- Earnings2(8%)
- Leadership1(4%)
- Analyst1(4%)
Activity · 52 weeks10661 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- 13D/GSEC Form SCHEDULE 13G filed by REGENXBIO Inc.SCHEDULE 13G - REGENXBIO Inc. (0001590877) (Subject)
- SECSEC Form 10-Q filed by REGENXBIO Inc.10-Q - REGENXBIO Inc. (0001590877) (Filer)
- SECREGENXBIO Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - REGENXBIO Inc. (0001590877) (Filer)
- PRREGENXBIO Reports Third Quarter 2026 Financial Results and Operational HighlightsRGX-202 BLA submission for Duchenne muscular dystrophy on track for Q1 2027, with potential accelerated approval in 2H 2027Topline data from pivotal subretinal wet AMD studies, ATMOSPHERE® and ASCENT®, expected in Q4 2026Phase IIb/III NAAVIGATE trial for diabetic retinopathy ongoing Webcast today at 8:00 a.m. ET ROCKVILLE, Md., Nov. 5, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today reported financial results and operational highlights for the third quarter ended September 30, 2026."We are continuing to build momentum as we prepare to launch potential first- or best-in-class gene therapies in 2027 and 2028," said Curran Simpson, President and Chief Executive Officer of REGENXBIO. "Wi
- INSIDERChief Technology Officer Malzahn Craig was granted 27,777 shares, increasing direct ownership by 34% to 109,737 units (SEC Form 4)4 - REGENXBIO Inc. (0001590877) (Issuer)
- INSIDERChief Strategy & Legal Officer Christmas Patrick J. was granted 34,722 shares, increasing direct ownership by 17% to 240,690 units (SEC Form 4)4 - REGENXBIO Inc. (0001590877) (Issuer)
- INSIDERChief Medical Officer Pakola Steve was granted 34,722 shares, increasing direct ownership by 17% to 240,263 units (SEC Form 4)4 - REGENXBIO Inc. (0001590877) (Issuer)
- INSIDERChief Financial Officer Chan Mitchell was granted 24,305 shares, increasing direct ownership by 20% to 147,120 units (SEC Form 4)4 - REGENXBIO Inc. (0001590877) (Issuer)
- PRREGENXBIO to Participate in Stifel 2026 Healthcare ConferenceROCKVILLE, Md., Nov. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced it will participate in the Stifel 2026 Healthcare Conference. Fireside Chat DetailsDate and Time: Wednesday, November 11, 2026 at 9:20 a.m. ET Location: New York, NYA live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcasts will be available for approximately 30 days following the event.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENX
- PRREGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational HighlightsROCKVILLE, Md., Oct. 29, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Thursday, November 5, at 8:00 a.m. ET to discuss its financial results for the third quarter ended September 30, 2026, and operational highlights.Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mi
- SECSEC Form 8-K filed by REGENXBIO Inc.8-K - REGENXBIO Inc. (0001590877) (Filer)
- SECSEC Form SCHEDULE 13G filed by REGENXBIO Inc.SCHEDULE 13G - REGENXBIO Inc. (0001590877) (Subject)
- PRREGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20Event to include clinical program overview and perspectives from leading retina specialists ahead of topline pivotal data readout anticipated in 4Q 2026ROCKVILLE, Md., Oct. 12, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced it will host an investor event at 1:00 p.m. ET on Tuesday, October 20, 2026 to review the surabgene lomparvovec (sura-vec, ABBV-RGX-314) clinical program in wet age-related macular degeneration (wet AMD) ahead of the topline pivotal data anticipated in the fourth quarter of 2026. The event will be held in-person in New York, NY and available via webcast.Along with a clinical program overview, the event will feature perspectives from REGENXBIO management
- ANALYSTMizuho initiated coverage on REGENXBIO with a new price targetMizuho initiated coverage of REGENXBIO with a rating of Outperform and set a new price target of $22.00
- PRREGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific MeetingMajority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no additional treatment for diabetic retinopathyNo IOI observed with short-course prophylactic topical steroidsROCKVILLE, Md., Sept. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive long-term follow-up data from the Phase II ALTITUDE® study of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery. These new data were presented at the Retina Society 59th Annual Scientific Meeting in Los Angeles."These l
- SECREGENXBIO Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - REGENXBIO Inc. (0001590877) (Filer)
- PRREGENXBIO to Participate in Upcoming Investor ConferencesROCKVILLE, Md., Sept. 8, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:Baird 2026 Global Healthcare ConferenceFireside Chat: Tuesday, September 15 at 8:30 a.m. ETLocation: New York, NY Morgan Stanley 24th Annual Global Healthcare ConferenceFireside Chat: Wednesday, September 16 at 8:30 a.m. ETLocation: New York, NYLive webcasts of select events can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. Archived replays of the webcasts will be available for approximately 30 days following the events.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives thr
- INSIDERChief Technology Officer Malzahn Craig covered exercise/tax liability with 234 shares, decreasing direct ownership by 0.28% to 81,960 units (SEC Form 4)4 - REGENXBIO Inc. (0001590877) (Issuer)
- INSIDERChief Financial Officer Chan Mitchell covered exercise/tax liability with 4,902 shares, decreasing direct ownership by 4% to 122,815 units (SEC Form 4)4 - REGENXBIO Inc. (0001590877) (Issuer)
- INSIDERDirector Ciongoli Gregory Austin was granted 15,432 shares and bought $949,381 worth of shares (102,603 units at $9.25) (SEC Form 4)4 - REGENXBIO Inc. (0001590877) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ciongoli Gregory Austin3 - REGENXBIO Inc. (0001590877) (Issuer)
- SECREGENXBIO Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - REGENXBIO Inc. (0001590877) (Filer)
- PRREGENXBIO Strengthens Board of Directors with Appointment of Greg CiongoliROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming catalysts across its late-stage pipeline of potential first-and best-in-class gene therapies, Mr. Ciongoli joins the Board as REGENXBIO prepares to become a global commercial organization. Mr. Ciongoli has extensive experience in biotechnology investing, capital allocation and corporate strategy to support the Company's next phase of growth.Concurrent with Mr. Ciongoli's appointment and following years of distinguished service, Jerry Karabelas, Ph.D., who served as an independent director since
- SECREGENXBIO Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - REGENXBIO Inc. (0001590877) (Filer)
- PRREGENXBIO Announces Regulatory Update on RGX-121 for MPS IIROCKVILLE, Md., Aug. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome. The U.S. Food and Drug Administration (FDA) placed a clinical hold on RGX-121 following the discovery of asymptomatic spine MRI findings in five participants in the CAMPSIITE® study; REGENXBIO does not expect to resubmit the RGX-121 Biologics License Application (BLA) in the near term."We believe these findings are unique and limited to our Hunter Syndrome program, and require longer-term follow-up and additional data analysis to a
RGNX FAQ
11 questionsWhat does REGENXBIO Inc. do?
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II...What is the latest news on RGNX?
In the last 30 days Quantisnow tracked 10 wire items for RGNX: 4 insider trades, 2 earnings updates, 2 SEC filings and 1 press release or news item. The most recent was published on November 10, 2026.What is RGNX revenue?
REGENXBIO Inc. (RGNX) reported $153.91M of revenue for the twelve months ended Sep 30, 2026. That is down 4.6% from the year before. Revenue for fiscal 2025 was $170.44M.Is RGNX profitable?
No. REGENXBIO Inc. reported a net loss of $175.23M for the twelve months ended Sep 30, 2026.How much cash and debt does RGNX have?
REGENXBIO Inc. reported $95.80M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does RGNX stock trade?
REGENXBIO Inc. (RGNX) is listed on NASDAQ.What sector and industry is RGNX in?
REGENXBIO Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did REGENXBIO Inc. go public?
REGENXBIO Inc. (RGNX) completed its IPO in 2015.What are analysts saying about RGNX?
Across the last 8 analyst actions on REGENXBIO Inc., there were 0 upgrades and 2 downgrades. The most recent action was from Mizuho: Outperform with a $22.00 price target on 2026-10-05. Recent price targets range from $12.00 to $38.00.What companies are similar to RGNX?
Notable peers in the same industry include FDMT (4D Molecular Therapeutics Inc.), RCKT (Rocket Pharmaceuticals Inc.), RARE (Ultragenyx Pharmaceutical Inc.), OCGN (Ocugen Inc.), SRPT (Sarepta Therapeutics Inc.). Compare RGNX side-by-side with any of them on Quantisnow.How can I track RGNX on Quantisnow?
Quantisnow aggregates REGENXBIO Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RGNX to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change